SlideShare a Scribd company logo
Prophylaxis and Treatment of Opportunistic
Infections in HIV Patient
Toxoplasmosis
Dr Hythum Salah H. Mohamed .
MBBS-AAHIVS .
King Abdulaziz Medical City-IM-ID-Riyadh ..May 2014
 Toxoplasma-seropositive patients who have CD4 counts <100
cells/μL should receive prophylaxis against TE (toxoplasma
Encephalitis ) (AII) .
 The one double-strength-tablet daily dose of trimethoprim-
sulfamethoxazole (TMP-SMX), which is the preferred regimen for
Pneumocystis jirovecii pneumonia (PCP) prophylaxis, is effective
against TE and is recommended ( AII) .
 TMP-SMX, one double-strength tablet three times weekly, is an
alternative (BIII) .
 dapsone-pyrimethamine plus leucovorin, which is also effective
against PCP (BI) .
aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults
Primary Prophylaxis
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 Aerosolized pentamidine does not protect against TE and is not
recommended for antitoxoplasma prophylaxis (AI).
 Prophylaxis against TE should be discontinued in adult and
adolescent patients receiving ART whose CD4 counts increase to
>200 cells/μL for more than 3 months
 Preferred Regimen:
 • TMP-SMX 1 DS PO daily (AII)
 Alternative Regimens:
 • TMP-SMX 1 DS PO TIW (BIII), or
 • TMP-SMX SS PO daily (BIII), or
 • Dapsone 50 mg PO daily + (pyrimethamine 50 mg + leucovorin 25 mg) PO weekly (BI),
or
 • (Dapsone 200 mg + pyrimethamine 75 mg + leucovorin 25 mg) PO weekly (BI), or
 • Atovaquone 1500 mg PO daily (CIII), or
aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 Start after acute treatment of toxoplasmosis .
 combination of pyrimethamine plus sulfadiazine plus leucovorin is
highly effective as suppressive therapy for patients with TE (AI) and
provides protection against PCP (AII) .
 Pyrimethamine plus clindamycin is commonly used as suppressive
therapy for patients with TE who cannot tolerate sulfa drugs (BI) not
provide protection against PCP (AII) .
Pyrimethamine 25–50 mg PO daily + sulfadiazine 2000–4000 mg PO
daily (in 2 to 4 divided doses) + leucovorin 10–25 mg PO daily (AI).
 Alternative Regimen:
Clindamycin 600 mg PO q8h + (pyrimethamine 25–50 mg +
leucovorin 10–25 mg) PO daily (BI); must add additional agent to
prevent PCP (AII)
aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults
Secondary Prophylaxis
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 Duration and discontinuation : Patient who remain asymptomatic
with regard to signs and symptoms of TE, and have an increase in
their CD4 counts to >200 cells/μL after ART that is sustained for more
than 6 months (BI) .
 Secondary prophylaxis (chronic maintenance therapy) for TE should
be reintroduced if the CD4 count decreases to <200 cells/μL (AIII).
aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults
 For many patients, we use TMP-SMX (TMP 5 mg/kg/day - SMX
25 mg/kg/day) for secondary prophylaxis to help reduce pill
burden.
 This regimen is not recommended in standard guidelines because
of the lack of sufficient clinical trial data.
www.uptodate.com/
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 The initial therapy of choice for TE consists of the combination of
pyrimethamine plus sulfadiazine plus leucovorin (AI) .
 Pyrimethamine plus clindamycin plus leucovorin (AI) is the preferred
alternative .
 In a small (77 patients) randomized trial, TMP-SMX was reported to
be effective and better tolerated than pyrimethamine-sulfadiazine
(BI) .
 Azithromycin plus pyrimethamine plus leucovorin daily (CII).
 Clinical response to acute therapy occurs in 90% of patients with TE
within 14 days of initiation of appropriate anti-toxoplasma treatment
 Acute therapy for TE should be continued for at least 6 weeks, if
there is clinical and radiologic improvement (BII) .
aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults
Treatment of Disease
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 The initial therapy of choice for TE consists of the combination of
pyrimethamine plus sulfadiazine plus leucovorin (AI).
 TMP-SMX was reported in a small (77 patients) randomized trial to
be effective and better tolerated than pyrimethamine-
sulfadiazine (BI).
www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm
 there are limited data, it appears that AIDS patients with extra
cerebral toxoplasmosis respond to pyrimethamine plus either
sulfadiazine or clindamycin. The mortality rate in patients with
pulmonary or disseminated toxoplasmosis may be higher than in
patients with toxoplasmic encephalitis alone .
www.hivinsite.ucsf.edu/InSite.
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 Corticosteroids such as dexamethasone should only be
administered to patients with TE when they are clinically indicated
to treat a mass effect associated with focal lesions or associated
edema (BIII) .
 Anticonvulsants should be administered to patients with TE who
have a history of seizures (AIII) .
 Anticonvulsants should not be administered prophylactically to all
patients (BIII).
 Anticonvulsants, if administered, should be continued at least
through the period of acute therapy.
aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults
Steroids and Anticonvulsant
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 There are no data on which to base a recommendation regarding
when to start ART in a patient with TE , however, many physicians
would initiate ART within 2 to 3 weeks after the diagnosis of
toxoplasmosis(CIII) .
aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults

Antiretroviral therapy (ART) should be initiated within two to three
weeks of starting treatment for toxoplasmosis , this recommendation
is based upon expert opinion.
www.uptodate.com
Starting ART
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 Baseline maternal T. gondii serologic status (IgG) should be obtained
in HIV-infected pregnant women .
 Maternal treatment of TE should be the same as in non-pregnant
adults (BIII) .
 pyrimethamine plus Sulfadiazine plus leucovorin (AI) .
 The above regimen is also believed to prevent mother-to-child
transmission of T. gondii and it may be therapeutic for affected
fetuses .
 The preferred alternative regimen is pyrimethamine plus
clindamycin plus leucovorin (AI).
aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults
Special Considerations During Pregnancy
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 Detailed ultrasound examination of the fetus specifically evaluating
for hydrocephalus, cerebral calcifications, and growth restriction
should be done for HIV-infected women with suspected primary or
symptomatic reactivation of T. gondii during pregnancy (AIII).
 TMP-SMX can be administered for primary prophylaxis against TE
(AIII). The risks of TMP-SMX in the first trimester must be balanced
against the risk of TE.
 Perinatal HIV transmission is decrease by 6% to 8% per week of ART,
clinicians should consider immediate initiation of ART for pregnant
women who are diagnosed with TE and not yet on ART (BIII) .
aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 Treatment Failure is defined by clinical or radiologic deterioration
during the first week despite adequate therapy or lack of clinical
improvement within 2 weeks .
 Switch to an alternative regimen as previously described should be
considered (BIII) .
 A brain biopsy, if not previously performed, should be strongly
considered for patients who fail to respond to initial therapy for TE
(BII) .
www.cdc.gov/.
Treatment Failure
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 Changes in antibody titers are not useful for monitoring
responses to therapy.
 Patients with TE should be monitored routinely for adverse events
and clinical and radiologic improvement (AIII).
 Common pyrimethamine toxicities such as rash, nausea, and
bone marrow suppression , often can be reversed by increasing
the leucovorin dose to 10, 25, or 50 mg 4 times daily (CIII).
 IRIS associated with TE has been reported but appears to be
rare (~5% in one report).
Monitoring of Response to Therapy and
Adverse Events (including IRIS)
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014
 Toxoplasma Encephalitis is AIDS defining illness .
 Primary Prophylaxis indicated when CD4 count is <100 .
 Primary Prophylaxis TMP-SMX 1 DS PO daily (AII) .
 Secondary Prophylaxis is Pyrimethamine + sulfadiazine + leucovor PO
daily (AI) .
 Discontinue secondary prophylaxis when Successfully completed initial
therapy, remain asymptomatic of signs and symptoms of TE, and CD4
count >200 cells/mm3 for >6 months in response to ART (BI)
 The initial therapy of choice for TE consists of the combination of
pyrimethamine plus sulfadiazine plus leucovorin (AI) at least for six seeks
(BII) .
 Maternal treatment of TE should be the same as in non-pregnant adults
(BIII).
aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults
Conclusions
Dr Hythum Salah
KAMC-IM-ID-Riyadh ..May 2014

More Related Content

What's hot

Final Journal Club Presentation
Final Journal Club PresentationFinal Journal Club Presentation
Final Journal Club PresentationAnna Schemel
 
Treat the Patient: Not the Pregnancy April 2015
Treat the Patient: Not the Pregnancy April 2015Treat the Patient: Not the Pregnancy April 2015
Treat the Patient: Not the Pregnancy April 2015
PASaskatchewan
 
Arv guideline2014 (1)
Arv guideline2014 (1)Arv guideline2014 (1)
Arv guideline2014 (1)
Nasibah Tuan Yaacob
 
REVIEWED malaria drug policy in ghana
REVIEWED  malaria drug policy in ghanaREVIEWED  malaria drug policy in ghana
REVIEWED malaria drug policy in ghana
Gideon Dzando
 
Covid19 Vaccination in India
Covid19 Vaccination in IndiaCovid19 Vaccination in India
Covid19 Vaccination in India
Narasimha Reddy Donthi
 
COVID-19 Vaccination in Pregnancy & Breastfeeding
COVID-19 Vaccination in Pregnancy & BreastfeedingCOVID-19 Vaccination in Pregnancy & Breastfeeding
COVID-19 Vaccination in Pregnancy & Breastfeeding
Institute for Clinical Research (ICR)
 
Key Facts over HIV by Dr. Milind Kulkarni
Key Facts over HIV by Dr. Milind KulkarniKey Facts over HIV by Dr. Milind Kulkarni
Key Facts over HIV by Dr. Milind Kulkarni
Parvez Pathan
 
COVID-19 Vaccination in Patients Requiring Palliative Care
COVID-19 Vaccination in Patients Requiring Palliative CareCOVID-19 Vaccination in Patients Requiring Palliative Care
COVID-19 Vaccination in Patients Requiring Palliative Care
Institute for Clinical Research (ICR)
 
Vaccines in immunocompromised children - Slideset by Professor Kathryn Edwards
Vaccines in immunocompromised children - Slideset by Professor Kathryn EdwardsVaccines in immunocompromised children - Slideset by Professor Kathryn Edwards
Vaccines in immunocompromised children - Slideset by Professor Kathryn Edwards
WAidid
 
Vaccine Side Effects: Haematology Related
Vaccine Side Effects: Haematology RelatedVaccine Side Effects: Haematology Related
Vaccine Side Effects: Haematology Related
Institute for Clinical Research (ICR)
 
Perception and Behavioural Outcome towards COVID-19 Vaccine among Students an...
Perception and Behavioural Outcome towards COVID-19 Vaccine among Students an...Perception and Behavioural Outcome towards COVID-19 Vaccine among Students an...
Perception and Behavioural Outcome towards COVID-19 Vaccine among Students an...
Kailash Nagar
 
Immunization special situations and AEFI
Immunization   special situations and AEFIImmunization   special situations and AEFI
Immunization special situations and AEFI
Lokanath Reddy Mummadi
 
Guidelines On COVID-19 Vaccination In Pregnancy And Breastfeeding
Guidelines On COVID-19 Vaccination In Pregnancy And BreastfeedingGuidelines On COVID-19 Vaccination In Pregnancy And Breastfeeding
Guidelines On COVID-19 Vaccination In Pregnancy And Breastfeeding
Institute for Clinical Research (ICR)
 
Palliative care in COVID-19
Palliative care in COVID-19Palliative care in COVID-19
Palliative care in COVID-19
Institute for Clinical Research (ICR)
 
COVID in Pregnancy
COVID in PregnancyCOVID in Pregnancy
COVID in Pregnancy
Dr.Laxmi Agrawal Shrikhande
 
Prevention of Parent To Child Transmission PPTCT
Prevention of Parent To Child Transmission PPTCTPrevention of Parent To Child Transmission PPTCT
Prevention of Parent To Child Transmission PPTCTDrShruthi Pradeep
 
IMA perspective of pharmacovigilance
IMA perspective of pharmacovigilanceIMA perspective of pharmacovigilance
IMA perspective of pharmacovigilance
PHARMAQUEST Vydehi
 
How to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseasesHow to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseases
Faculty of Medicine
 

What's hot (19)

Final Journal Club Presentation
Final Journal Club PresentationFinal Journal Club Presentation
Final Journal Club Presentation
 
Treat the Patient: Not the Pregnancy April 2015
Treat the Patient: Not the Pregnancy April 2015Treat the Patient: Not the Pregnancy April 2015
Treat the Patient: Not the Pregnancy April 2015
 
Arv guideline2014 (1)
Arv guideline2014 (1)Arv guideline2014 (1)
Arv guideline2014 (1)
 
Ped hiv
Ped  hivPed  hiv
Ped hiv
 
REVIEWED malaria drug policy in ghana
REVIEWED  malaria drug policy in ghanaREVIEWED  malaria drug policy in ghana
REVIEWED malaria drug policy in ghana
 
Covid19 Vaccination in India
Covid19 Vaccination in IndiaCovid19 Vaccination in India
Covid19 Vaccination in India
 
COVID-19 Vaccination in Pregnancy & Breastfeeding
COVID-19 Vaccination in Pregnancy & BreastfeedingCOVID-19 Vaccination in Pregnancy & Breastfeeding
COVID-19 Vaccination in Pregnancy & Breastfeeding
 
Key Facts over HIV by Dr. Milind Kulkarni
Key Facts over HIV by Dr. Milind KulkarniKey Facts over HIV by Dr. Milind Kulkarni
Key Facts over HIV by Dr. Milind Kulkarni
 
COVID-19 Vaccination in Patients Requiring Palliative Care
COVID-19 Vaccination in Patients Requiring Palliative CareCOVID-19 Vaccination in Patients Requiring Palliative Care
COVID-19 Vaccination in Patients Requiring Palliative Care
 
Vaccines in immunocompromised children - Slideset by Professor Kathryn Edwards
Vaccines in immunocompromised children - Slideset by Professor Kathryn EdwardsVaccines in immunocompromised children - Slideset by Professor Kathryn Edwards
Vaccines in immunocompromised children - Slideset by Professor Kathryn Edwards
 
Vaccine Side Effects: Haematology Related
Vaccine Side Effects: Haematology RelatedVaccine Side Effects: Haematology Related
Vaccine Side Effects: Haematology Related
 
Perception and Behavioural Outcome towards COVID-19 Vaccine among Students an...
Perception and Behavioural Outcome towards COVID-19 Vaccine among Students an...Perception and Behavioural Outcome towards COVID-19 Vaccine among Students an...
Perception and Behavioural Outcome towards COVID-19 Vaccine among Students an...
 
Immunization special situations and AEFI
Immunization   special situations and AEFIImmunization   special situations and AEFI
Immunization special situations and AEFI
 
Guidelines On COVID-19 Vaccination In Pregnancy And Breastfeeding
Guidelines On COVID-19 Vaccination In Pregnancy And BreastfeedingGuidelines On COVID-19 Vaccination In Pregnancy And Breastfeeding
Guidelines On COVID-19 Vaccination In Pregnancy And Breastfeeding
 
Palliative care in COVID-19
Palliative care in COVID-19Palliative care in COVID-19
Palliative care in COVID-19
 
COVID in Pregnancy
COVID in PregnancyCOVID in Pregnancy
COVID in Pregnancy
 
Prevention of Parent To Child Transmission PPTCT
Prevention of Parent To Child Transmission PPTCTPrevention of Parent To Child Transmission PPTCT
Prevention of Parent To Child Transmission PPTCT
 
IMA perspective of pharmacovigilance
IMA perspective of pharmacovigilanceIMA perspective of pharmacovigilance
IMA perspective of pharmacovigilance
 
How to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseasesHow to minimize therapeutic failure in infectious diseases
How to minimize therapeutic failure in infectious diseases
 

Viewers also liked

Guia prevencion y tx infecciones oportunistas por vih
Guia prevencion y tx infecciones oportunistas por vihGuia prevencion y tx infecciones oportunistas por vih
Guia prevencion y tx infecciones oportunistas por vih
Deisy de Jesus
 
Opportunistic Infection Among Hiv Infected Children
Opportunistic Infection Among Hiv Infected ChildrenOpportunistic Infection Among Hiv Infected Children
Opportunistic Infection Among Hiv Infected ChildrenDang Thanh Tuan
 
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...MedicineAndHealthUSA
 
Blood components
Blood componentsBlood components
Blood components
Shahin Hameed
 
Hiv and opportunistic infections
Hiv and opportunistic infectionsHiv and opportunistic infections
Hiv and opportunistic infections
aishuanju
 
Opportunistic infections and aids
Opportunistic infections and aidsOpportunistic infections and aids
Opportunistic infections and aidsacatanzaro
 
Hiv and oppurtunistic infections
Hiv and oppurtunistic infectionsHiv and oppurtunistic infections
Hiv and oppurtunistic infections
me2432 j
 
Module 3 opportunistic infections and hiv related conditi
Module 3  opportunistic infections and hiv  related  conditiModule 3  opportunistic infections and hiv  related  conditi
Module 3 opportunistic infections and hiv related conditiDavid Ngogoyo
 
Opportunistic infections
Opportunistic infectionsOpportunistic infections
Opportunistic infectionsDr.Vijay Talla
 
Blood components and its uses
Blood components and its usesBlood components and its uses
Blood components and its uses
Anish Gupta
 
Characteristics of benign and malignant neoplasms
Characteristics of benign and malignant neoplasmsCharacteristics of benign and malignant neoplasms
Characteristics of benign and malignant neoplasmsLiezle Joy Gargoles
 
Neoplasia Characteristics and classification of cancer
Neoplasia Characteristics and classification of cancerNeoplasia Characteristics and classification of cancer
Neoplasia Characteristics and classification of cancerSubramani Parasuraman
 
Tumors
TumorsTumors
Prevention Of HIV/AIDS
Prevention Of HIV/AIDSPrevention Of HIV/AIDS
Prevention Of HIV/AIDSSoumar Dutta
 
Blood and its components
Blood and its componentsBlood and its components
Blood and its componentsjunni86
 
Hiv associated opportunistic infections
Hiv associated opportunistic infectionsHiv associated opportunistic infections
Hiv associated opportunistic infections
Ivan Luyimbazi
 

Viewers also liked (19)

Guia prevencion y tx infecciones oportunistas por vih
Guia prevencion y tx infecciones oportunistas por vihGuia prevencion y tx infecciones oportunistas por vih
Guia prevencion y tx infecciones oportunistas por vih
 
Tumours
TumoursTumours
Tumours
 
Opportunistic Infection Among Hiv Infected Children
Opportunistic Infection Among Hiv Infected ChildrenOpportunistic Infection Among Hiv Infected Children
Opportunistic Infection Among Hiv Infected Children
 
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...
 
Blood components
Blood componentsBlood components
Blood components
 
HIV Opportunistic Infections Iralu
HIV Opportunistic Infections IraluHIV Opportunistic Infections Iralu
HIV Opportunistic Infections Iralu
 
Hiv and opportunistic infections
Hiv and opportunistic infectionsHiv and opportunistic infections
Hiv and opportunistic infections
 
Opportunistic infections and aids
Opportunistic infections and aidsOpportunistic infections and aids
Opportunistic infections and aids
 
Hiv and oppurtunistic infections
Hiv and oppurtunistic infectionsHiv and oppurtunistic infections
Hiv and oppurtunistic infections
 
Module 3 opportunistic infections and hiv related conditi
Module 3  opportunistic infections and hiv  related  conditiModule 3  opportunistic infections and hiv  related  conditi
Module 3 opportunistic infections and hiv related conditi
 
Opportunistic infections (oi) deepa
Opportunistic infections (oi) deepaOpportunistic infections (oi) deepa
Opportunistic infections (oi) deepa
 
Opportunistic infections
Opportunistic infectionsOpportunistic infections
Opportunistic infections
 
Blood components and its uses
Blood components and its usesBlood components and its uses
Blood components and its uses
 
Characteristics of benign and malignant neoplasms
Characteristics of benign and malignant neoplasmsCharacteristics of benign and malignant neoplasms
Characteristics of benign and malignant neoplasms
 
Neoplasia Characteristics and classification of cancer
Neoplasia Characteristics and classification of cancerNeoplasia Characteristics and classification of cancer
Neoplasia Characteristics and classification of cancer
 
Tumors
TumorsTumors
Tumors
 
Prevention Of HIV/AIDS
Prevention Of HIV/AIDSPrevention Of HIV/AIDS
Prevention Of HIV/AIDS
 
Blood and its components
Blood and its componentsBlood and its components
Blood and its components
 
Hiv associated opportunistic infections
Hiv associated opportunistic infectionsHiv associated opportunistic infections
Hiv associated opportunistic infections
 

Similar to Prophylaxis and treatment of opportunistic infections in HIV patients

02.02 adult art initiation gsn
02.02 adult  art initiation gsn02.02 adult  art initiation gsn
02.02 adult art initiation gsnDavid Ngogoyo
 
Idiopathic Thrombocytopenic Purpura
Idiopathic Thrombocytopenic PurpuraIdiopathic Thrombocytopenic Purpura
Idiopathic Thrombocytopenic PurpuraDang Thanh Tuan
 
GFATM training for nurses
GFATM training for nursesGFATM training for nurses
GFATM training for nurses
anjalatchi
 
GFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptxGFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptx
naveenithkrishnan
 
TPT in the field of medicine overview . f.pptx
TPT in the field of medicine overview . f.pptxTPT in the field of medicine overview . f.pptx
TPT in the field of medicine overview . f.pptx
PhilemonChizororo
 
coinfections-tuberculosis-tb-adult-adolescent-arv.pdf
coinfections-tuberculosis-tb-adult-adolescent-arv.pdfcoinfections-tuberculosis-tb-adult-adolescent-arv.pdf
coinfections-tuberculosis-tb-adult-adolescent-arv.pdf
suyogspatil
 
Management of tuberculosis in special situation and MDR TB.
Management of tuberculosis in special situation and MDR TB.Management of tuberculosis in special situation and MDR TB.
Management of tuberculosis in special situation and MDR TB.
NUR PUNAM
 
Cryptococcal meningitis
Cryptococcal meningitisCryptococcal meningitis
03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiat03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiatDavid Ngogoyo
 
Anti retroviral therapy in children
Anti retroviral therapy  in childrenAnti retroviral therapy  in children
Anti retroviral therapy in children
subhash chettri
 
Ibalizumab - Journal Club Handout (Holden Young - Roseman University of Healt...
Ibalizumab - Journal Club Handout (Holden Young - Roseman University of Healt...Ibalizumab - Journal Club Handout (Holden Young - Roseman University of Healt...
Ibalizumab - Journal Club Handout (Holden Young - Roseman University of Healt...
HoldenYoung3
 
Covid 19 advancement in treatment over time
Covid 19 advancement in treatment over timeCovid 19 advancement in treatment over time
Covid 19 advancement in treatment over time
DR.pankaj omar
 
A team 7th GCC
A team 7th  GCCA team 7th  GCC
ITP.ppt
ITP.pptITP.ppt
ITP.ppt
Shravankch
 
Hiv.ppt
Hiv.pptHiv.ppt
Tuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM FoundationTuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM Foundation
The CRUDEM Foundation
 
Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019
Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019
Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019
Meningitis Research Foundation
 
Post Exposure Prophylaxis by Dr Dele
Post Exposure Prophylaxis by Dr DelePost Exposure Prophylaxis by Dr Dele
Post Exposure Prophylaxis by Dr Dele
Kemi Dele-Ijagbulu
 
Immunization in children with cancer
Immunization in children with cancerImmunization in children with cancer
Immunization in children with cancer
Dr. Renesha Islam
 

Similar to Prophylaxis and treatment of opportunistic infections in HIV patients (20)

02.02 adult art initiation gsn
02.02 adult  art initiation gsn02.02 adult  art initiation gsn
02.02 adult art initiation gsn
 
Idiopathic Thrombocytopenic Purpura
Idiopathic Thrombocytopenic PurpuraIdiopathic Thrombocytopenic Purpura
Idiopathic Thrombocytopenic Purpura
 
Itp
ItpItp
Itp
 
GFATM training for nurses
GFATM training for nursesGFATM training for nurses
GFATM training for nurses
 
GFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptxGFATM trainning for Nurses.pptx
GFATM trainning for Nurses.pptx
 
TPT in the field of medicine overview . f.pptx
TPT in the field of medicine overview . f.pptxTPT in the field of medicine overview . f.pptx
TPT in the field of medicine overview . f.pptx
 
coinfections-tuberculosis-tb-adult-adolescent-arv.pdf
coinfections-tuberculosis-tb-adult-adolescent-arv.pdfcoinfections-tuberculosis-tb-adult-adolescent-arv.pdf
coinfections-tuberculosis-tb-adult-adolescent-arv.pdf
 
Management of tuberculosis in special situation and MDR TB.
Management of tuberculosis in special situation and MDR TB.Management of tuberculosis in special situation and MDR TB.
Management of tuberculosis in special situation and MDR TB.
 
Cryptococcal meningitis
Cryptococcal meningitisCryptococcal meningitis
Cryptococcal meningitis
 
03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiat03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiat
 
Anti retroviral therapy in children
Anti retroviral therapy  in childrenAnti retroviral therapy  in children
Anti retroviral therapy in children
 
Ibalizumab - Journal Club Handout (Holden Young - Roseman University of Healt...
Ibalizumab - Journal Club Handout (Holden Young - Roseman University of Healt...Ibalizumab - Journal Club Handout (Holden Young - Roseman University of Healt...
Ibalizumab - Journal Club Handout (Holden Young - Roseman University of Healt...
 
Covid 19 advancement in treatment over time
Covid 19 advancement in treatment over timeCovid 19 advancement in treatment over time
Covid 19 advancement in treatment over time
 
A team 7th GCC
A team 7th  GCCA team 7th  GCC
A team 7th GCC
 
ITP.ppt
ITP.pptITP.ppt
ITP.ppt
 
Hiv.ppt
Hiv.pptHiv.ppt
Hiv.ppt
 
Tuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM FoundationTuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM Foundation
 
Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019
Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019
Dr Muhamed-Kheir Taha @ MRF's Meningitis and Septicaemia 2019
 
Post Exposure Prophylaxis by Dr Dele
Post Exposure Prophylaxis by Dr DelePost Exposure Prophylaxis by Dr Dele
Post Exposure Prophylaxis by Dr Dele
 
Immunization in children with cancer
Immunization in children with cancerImmunization in children with cancer
Immunization in children with cancer
 

More from King Abdualziz Medical City -National Guard Health Affairs

Case Presentsion
Case Presentsion Case Presentsion
Mixed Fungal Pneumonia and Candidemia in Immunocompromised Patient -Case Pres...
Mixed Fungal Pneumonia and Candidemia in Immunocompromised Patient -Case Pres...Mixed Fungal Pneumonia and Candidemia in Immunocompromised Patient -Case Pres...
Mixed Fungal Pneumonia and Candidemia in Immunocompromised Patient -Case Pres...
King Abdualziz Medical City -National Guard Health Affairs
 
Chryseobacterium Indologenes Pneumonia -Case Presentation
 Chryseobacterium Indologenes Pneumonia -Case Presentation Chryseobacterium Indologenes Pneumonia -Case Presentation
Chryseobacterium Indologenes Pneumonia -Case Presentation
King Abdualziz Medical City -National Guard Health Affairs
 
Primary prophylaxis in humman immuno defieincy virus
Primary prophylaxis in humman immuno defieincy virusPrimary prophylaxis in humman immuno defieincy virus
Primary prophylaxis in humman immuno defieincy virus
King Abdualziz Medical City -National Guard Health Affairs
 
HIV (Human Immunodefincy Virus ) Infection in Pregnancy Eliminate Mother to ...
HIV (Human Immunodefincy Virus ) Infection in Pregnancy  Eliminate Mother to ...HIV (Human Immunodefincy Virus ) Infection in Pregnancy  Eliminate Mother to ...
HIV (Human Immunodefincy Virus ) Infection in Pregnancy Eliminate Mother to ...
King Abdualziz Medical City -National Guard Health Affairs
 
Ebola Hemorrhagic Fever Deadly African Virus
Ebola Hemorrhagic Fever          Deadly African Virus   Ebola Hemorrhagic Fever          Deadly African Virus
Ebola Hemorrhagic Fever Deadly African Virus
King Abdualziz Medical City -National Guard Health Affairs
 
Fatal Multiple Fungal Sinusitis in Neutropenic T- Cell Lymphoblastic Lymphoma...
Fatal Multiple Fungal Sinusitis in Neutropenic T- Cell Lymphoblastic Lymphoma...Fatal Multiple Fungal Sinusitis in Neutropenic T- Cell Lymphoblastic Lymphoma...
Fatal Multiple Fungal Sinusitis in Neutropenic T- Cell Lymphoblastic Lymphoma...
King Abdualziz Medical City -National Guard Health Affairs
 
Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...
Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...
Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...
King Abdualziz Medical City -National Guard Health Affairs
 
The First Case Report : Mycobacterium riyadhense Pneumonia Newly Diagnosed H...
The First Case Report : Mycobacterium riyadhense Pneumonia  Newly Diagnosed H...The First Case Report : Mycobacterium riyadhense Pneumonia  Newly Diagnosed H...
The First Case Report : Mycobacterium riyadhense Pneumonia Newly Diagnosed H...
King Abdualziz Medical City -National Guard Health Affairs
 
Acinetobater infection Updated Medical Microbiological View
Acinetobater infection Updated Medical Microbiological View Acinetobater infection Updated Medical Microbiological View
Acinetobater infection Updated Medical Microbiological View
King Abdualziz Medical City -National Guard Health Affairs
 
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
King Abdualziz Medical City -National Guard Health Affairs
 

More from King Abdualziz Medical City -National Guard Health Affairs (11)

Case Presentsion
Case Presentsion Case Presentsion
Case Presentsion
 
Mixed Fungal Pneumonia and Candidemia in Immunocompromised Patient -Case Pres...
Mixed Fungal Pneumonia and Candidemia in Immunocompromised Patient -Case Pres...Mixed Fungal Pneumonia and Candidemia in Immunocompromised Patient -Case Pres...
Mixed Fungal Pneumonia and Candidemia in Immunocompromised Patient -Case Pres...
 
Chryseobacterium Indologenes Pneumonia -Case Presentation
 Chryseobacterium Indologenes Pneumonia -Case Presentation Chryseobacterium Indologenes Pneumonia -Case Presentation
Chryseobacterium Indologenes Pneumonia -Case Presentation
 
Primary prophylaxis in humman immuno defieincy virus
Primary prophylaxis in humman immuno defieincy virusPrimary prophylaxis in humman immuno defieincy virus
Primary prophylaxis in humman immuno defieincy virus
 
HIV (Human Immunodefincy Virus ) Infection in Pregnancy Eliminate Mother to ...
HIV (Human Immunodefincy Virus ) Infection in Pregnancy  Eliminate Mother to ...HIV (Human Immunodefincy Virus ) Infection in Pregnancy  Eliminate Mother to ...
HIV (Human Immunodefincy Virus ) Infection in Pregnancy Eliminate Mother to ...
 
Ebola Hemorrhagic Fever Deadly African Virus
Ebola Hemorrhagic Fever          Deadly African Virus   Ebola Hemorrhagic Fever          Deadly African Virus
Ebola Hemorrhagic Fever Deadly African Virus
 
Fatal Multiple Fungal Sinusitis in Neutropenic T- Cell Lymphoblastic Lymphoma...
Fatal Multiple Fungal Sinusitis in Neutropenic T- Cell Lymphoblastic Lymphoma...Fatal Multiple Fungal Sinusitis in Neutropenic T- Cell Lymphoblastic Lymphoma...
Fatal Multiple Fungal Sinusitis in Neutropenic T- Cell Lymphoblastic Lymphoma...
 
Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...
Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...
Antiretroviral Treatment of Adult with HIV Infection The guidelines of Inter...
 
The First Case Report : Mycobacterium riyadhense Pneumonia Newly Diagnosed H...
The First Case Report : Mycobacterium riyadhense Pneumonia  Newly Diagnosed H...The First Case Report : Mycobacterium riyadhense Pneumonia  Newly Diagnosed H...
The First Case Report : Mycobacterium riyadhense Pneumonia Newly Diagnosed H...
 
Acinetobater infection Updated Medical Microbiological View
Acinetobater infection Updated Medical Microbiological View Acinetobater infection Updated Medical Microbiological View
Acinetobater infection Updated Medical Microbiological View
 
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
 

Recently uploaded

Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 

Recently uploaded (20)

Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 

Prophylaxis and treatment of opportunistic infections in HIV patients

  • 1. Prophylaxis and Treatment of Opportunistic Infections in HIV Patient Toxoplasmosis Dr Hythum Salah H. Mohamed . MBBS-AAHIVS . King Abdulaziz Medical City-IM-ID-Riyadh ..May 2014
  • 2.  Toxoplasma-seropositive patients who have CD4 counts <100 cells/μL should receive prophylaxis against TE (toxoplasma Encephalitis ) (AII) .  The one double-strength-tablet daily dose of trimethoprim- sulfamethoxazole (TMP-SMX), which is the preferred regimen for Pneumocystis jirovecii pneumonia (PCP) prophylaxis, is effective against TE and is recommended ( AII) .  TMP-SMX, one double-strength tablet three times weekly, is an alternative (BIII) .  dapsone-pyrimethamine plus leucovorin, which is also effective against PCP (BI) . aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults Primary Prophylaxis Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 3.  Aerosolized pentamidine does not protect against TE and is not recommended for antitoxoplasma prophylaxis (AI).  Prophylaxis against TE should be discontinued in adult and adolescent patients receiving ART whose CD4 counts increase to >200 cells/μL for more than 3 months  Preferred Regimen:  • TMP-SMX 1 DS PO daily (AII)  Alternative Regimens:  • TMP-SMX 1 DS PO TIW (BIII), or  • TMP-SMX SS PO daily (BIII), or  • Dapsone 50 mg PO daily + (pyrimethamine 50 mg + leucovorin 25 mg) PO weekly (BI), or  • (Dapsone 200 mg + pyrimethamine 75 mg + leucovorin 25 mg) PO weekly (BI), or  • Atovaquone 1500 mg PO daily (CIII), or aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 4.  Start after acute treatment of toxoplasmosis .  combination of pyrimethamine plus sulfadiazine plus leucovorin is highly effective as suppressive therapy for patients with TE (AI) and provides protection against PCP (AII) .  Pyrimethamine plus clindamycin is commonly used as suppressive therapy for patients with TE who cannot tolerate sulfa drugs (BI) not provide protection against PCP (AII) . Pyrimethamine 25–50 mg PO daily + sulfadiazine 2000–4000 mg PO daily (in 2 to 4 divided doses) + leucovorin 10–25 mg PO daily (AI).  Alternative Regimen: Clindamycin 600 mg PO q8h + (pyrimethamine 25–50 mg + leucovorin 10–25 mg) PO daily (BI); must add additional agent to prevent PCP (AII) aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults Secondary Prophylaxis Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 5.  Duration and discontinuation : Patient who remain asymptomatic with regard to signs and symptoms of TE, and have an increase in their CD4 counts to >200 cells/μL after ART that is sustained for more than 6 months (BI) .  Secondary prophylaxis (chronic maintenance therapy) for TE should be reintroduced if the CD4 count decreases to <200 cells/μL (AIII). aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults  For many patients, we use TMP-SMX (TMP 5 mg/kg/day - SMX 25 mg/kg/day) for secondary prophylaxis to help reduce pill burden.  This regimen is not recommended in standard guidelines because of the lack of sufficient clinical trial data. www.uptodate.com/ Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 6.  The initial therapy of choice for TE consists of the combination of pyrimethamine plus sulfadiazine plus leucovorin (AI) .  Pyrimethamine plus clindamycin plus leucovorin (AI) is the preferred alternative .  In a small (77 patients) randomized trial, TMP-SMX was reported to be effective and better tolerated than pyrimethamine-sulfadiazine (BI) .  Azithromycin plus pyrimethamine plus leucovorin daily (CII).  Clinical response to acute therapy occurs in 90% of patients with TE within 14 days of initiation of appropriate anti-toxoplasma treatment  Acute therapy for TE should be continued for at least 6 weeks, if there is clinical and radiologic improvement (BII) . aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults Treatment of Disease Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 7.  The initial therapy of choice for TE consists of the combination of pyrimethamine plus sulfadiazine plus leucovorin (AI).  TMP-SMX was reported in a small (77 patients) randomized trial to be effective and better tolerated than pyrimethamine- sulfadiazine (BI). www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm  there are limited data, it appears that AIDS patients with extra cerebral toxoplasmosis respond to pyrimethamine plus either sulfadiazine or clindamycin. The mortality rate in patients with pulmonary or disseminated toxoplasmosis may be higher than in patients with toxoplasmic encephalitis alone . www.hivinsite.ucsf.edu/InSite. Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 8.  Corticosteroids such as dexamethasone should only be administered to patients with TE when they are clinically indicated to treat a mass effect associated with focal lesions or associated edema (BIII) .  Anticonvulsants should be administered to patients with TE who have a history of seizures (AIII) .  Anticonvulsants should not be administered prophylactically to all patients (BIII).  Anticonvulsants, if administered, should be continued at least through the period of acute therapy. aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults Steroids and Anticonvulsant Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 9.  There are no data on which to base a recommendation regarding when to start ART in a patient with TE , however, many physicians would initiate ART within 2 to 3 weeks after the diagnosis of toxoplasmosis(CIII) . aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults  Antiretroviral therapy (ART) should be initiated within two to three weeks of starting treatment for toxoplasmosis , this recommendation is based upon expert opinion. www.uptodate.com Starting ART Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 10.  Baseline maternal T. gondii serologic status (IgG) should be obtained in HIV-infected pregnant women .  Maternal treatment of TE should be the same as in non-pregnant adults (BIII) .  pyrimethamine plus Sulfadiazine plus leucovorin (AI) .  The above regimen is also believed to prevent mother-to-child transmission of T. gondii and it may be therapeutic for affected fetuses .  The preferred alternative regimen is pyrimethamine plus clindamycin plus leucovorin (AI). aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults Special Considerations During Pregnancy Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 11.  Detailed ultrasound examination of the fetus specifically evaluating for hydrocephalus, cerebral calcifications, and growth restriction should be done for HIV-infected women with suspected primary or symptomatic reactivation of T. gondii during pregnancy (AIII).  TMP-SMX can be administered for primary prophylaxis against TE (AIII). The risks of TMP-SMX in the first trimester must be balanced against the risk of TE.  Perinatal HIV transmission is decrease by 6% to 8% per week of ART, clinicians should consider immediate initiation of ART for pregnant women who are diagnosed with TE and not yet on ART (BIII) . aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 12.  Treatment Failure is defined by clinical or radiologic deterioration during the first week despite adequate therapy or lack of clinical improvement within 2 weeks .  Switch to an alternative regimen as previously described should be considered (BIII) .  A brain biopsy, if not previously performed, should be strongly considered for patients who fail to respond to initial therapy for TE (BII) . www.cdc.gov/. Treatment Failure Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 13.  Changes in antibody titers are not useful for monitoring responses to therapy.  Patients with TE should be monitored routinely for adverse events and clinical and radiologic improvement (AIII).  Common pyrimethamine toxicities such as rash, nausea, and bone marrow suppression , often can be reversed by increasing the leucovorin dose to 10, 25, or 50 mg 4 times daily (CIII).  IRIS associated with TE has been reported but appears to be rare (~5% in one report). Monitoring of Response to Therapy and Adverse Events (including IRIS) Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014
  • 14.  Toxoplasma Encephalitis is AIDS defining illness .  Primary Prophylaxis indicated when CD4 count is <100 .  Primary Prophylaxis TMP-SMX 1 DS PO daily (AII) .  Secondary Prophylaxis is Pyrimethamine + sulfadiazine + leucovor PO daily (AI) .  Discontinue secondary prophylaxis when Successfully completed initial therapy, remain asymptomatic of signs and symptoms of TE, and CD4 count >200 cells/mm3 for >6 months in response to ART (BI)  The initial therapy of choice for TE consists of the combination of pyrimethamine plus sulfadiazine plus leucovorin (AI) at least for six seeks (BII) .  Maternal treatment of TE should be the same as in non-pregnant adults (BIII). aidsinfo.nih.gov/guidelines on 5/7/2013 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults Conclusions Dr Hythum Salah KAMC-IM-ID-Riyadh ..May 2014